RE: Thoughts16 Apr 2019 22:53
Thanks Researcher and Sul, some great points and spot on with the lion/vulture analogy. For a small cap pharma taking even a small chunk of the 11 million chronic onstructive pulmonary disease cases per annum in the US alone will be transformational. Hopefully the additional data for Tudorza and the new addition of Duaklir and world wide sales team will help push up the sales, I'm pretty confident they can do it,
RE Stifel, they do seem to be out on a limb and that article in the FT much more negative than most brokers who on average have a target of 62p
I was surprised by that dip to 24.65, perhaps a larger seller offloading? It bounced nicely to mid 30's and seems to be settling nicely at ~30p. Perhaps a bit of a rise before 1st May with the update of results and presumably details of the financial arrangements. I definitely think this could be doing very well over the next year or two. i will buy in this week and let's hope the market responds well to news on the 1st. GL guys